ADA Scientific Sessions 2025 Abstract
The Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide Attenuate Colon Cancer Development by Targeting HIF-1α Mediated Glucose Metabolism
Experiments in animalsInterventions
Papers by Yi Fen Xie
1 result
1 result